Shots: Qiagen to launch the QIAprep& Viral RNA UM Kit, designed to simplify and accelerate PCR swab analysis and remove key testing bottlenecks for Covid-19 and other RNA viruses The […]readmore
Tags : Novel
Shots: The two companies collaborated to discover and develop novel therapeutics interfering with the disease-causing transcriptional programs in cancer and other diseases. Quantro intends to revamp the scope of pharmacologic […]readmore
Shots: Dragonfly to receive $55M upfront, additional payments for development, regulatory and sales milestones plus royalties on sales of approved products. BMS to get exclusive option to license exclusive worldwide […]readmore
Shots: The $1B support is for the development, production and delivery of the vaccine with its initiation in H2’20 including a P-III trial with 30,000 participants and a pediatric trial.AZ […]readmore
Shots: Skyhawk will deploy its SkySTARTM platform to develop drug candidates targeting autoimmune and metabolic diseases and will receive an up front $600M/target while Merck get an option to exclusively […]readmore
Shots: Dyno to receive upfront, research funding, license fees, clinical, regulatory & sales milestones and royalties on WW sales. The company will also utilize its AI technology & its suite […]readmore
Shots: The collaboration leverages WuXi’s WuXiBody platform to develop high-affinity bispecific Ab targeting CCN2 for the treatment of cancer and fibrosis WuXi Biologics will be responsible for biologics discovery, process […]readmore
Shots: The approval is based on P-II FIGHT-202 (NCT02924376) study which involves assessing of Pemazyre (13.5 mg, qd) in adults with previously treated, locally advanced or metastatic cholangiocarcinoma with documented […]readmore
Shots: The approval is based on P-III OLYMPUS trial results assessing Jelmyto in 74 adults with LG UTUC to evaluate its safety, tolerability and tumor ablative effect across the US […]readmore
Shots: Fate to receive $50M up front and $50M equity investment at $31/ share and funding for the research and development of collaboration candidates through IND filing. The company will […]readmore